Intact IL-12 signaling is necessary for the generation of human natural killer cells with enhanced effector function after restimulation  by Simhadri, Venkateswara R. et al.
J ALLERGY CLIN IMMUNOL
NOVEMBER 2014
1190 LETTERS TO THE EDITORhomes than in suburban homes. However, we were surprised to
find that the rate of detectable cockroach allergen level was only
12.2% in urban residences, which is lowwhen compared with that
in other inner-city populations such as New Orleans (44%),7 with
Baltimore, Boston, New York, and St Louis having detectable
cockroach allergen levels of 40%.8 We speculate that this may
reflect the predominance of single-family dwellings in our urban
sample compared with high-density residential structures that are
present in many large cities. However, like many inner cities,
asthma morbidity and mortality is high among the urban
population.9 On the basis of these data, we suggest that although
cockroach exposure may partially explain high urban asthma
morbidity, it seems unlikely that cockroach allergen exposure is
the sole or even the major contributor to the high asthma burden
in Detroit children as has been suggested from other studies and
cities.10 Our data also emphasize the potential importance of
accounting for regional variation in key environmental allergen
exposures when designing optimal intervention strategies
directed toward different US urban populations.
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Intact IL-12 signaling is necessary for the
generation of human natural killer cells with
enhanced effector function after restimulation
To the Editor:
Natural killer (NK) cells are lymphocytes that are important for
host defense against viral and bacterial infections, as well as
malignant transformation. They have the capacity to kill target
cells and produce cytokines on activation without previous
sensitization. Although NK cells have been traditionally catego-
rized as members of the innate immune system, recent studies
have shown that NK cells have the ability to modify their effector
function based on previous cytokine stimulation, activating
receptor–mediated stimulation, or both.1-3 The first evidence
that NK cells can remember came from studies showing that
they mediated recall responses to haptens in mice lacking T and
B cells using a contact hypersensitivity model.4 NK cell memory
has also been demonstrated in viral infections by using murine
models.3 In these models NK cells acquired long-lived memory
to influenza A, vesicular stomatitis virus, and HIV antigens.5
Additionally, development of long-lived NK cell memory to
mouse cytomegalovirus infection was shown to be dependent
on IL-12–mediated signals.3,6 Even without exposure to specific
antigens, ex vivo short exposure of mouse and human NK cells
to activating cytokines, such as IL-12, IL-15, and IL-18, elicits
‘‘memory-like’’ properties that are defined as enhanced effector
functions after restimulation.1,7,8
In this study we tested the role of IL-12–mediated signals in the
in vitro generation of human NK cells with enhanced effector
function after restimulation. In our opinion the best method to
address this issue would involve the use of PBMCs from patients
with a deficiency in IL-12 or IL-12 receptor (IL-12R) because we
could then exclude that the NK cells used in the experiments had
been activated at any time in vivo by IL-12. We have previously
described a 19-month-old patient with an IL-12Rb1 deficiency
caused by a complex mutation at exon 14 in the IL12RB1 gene
(c.1623_1624delinsTT; p.Q541X).9 We showed that IFN-g
production was markedly decreased after stimulation of PBMCs
with PHA or PHA plus IL-12 and that therewas diminished signal
transducer and activator of transcription 4 phosphorylation after
IL-12 stimulation.9 Here we specifically tested whether the NK
cells from this patient responded to IL-12 stimulation. Flow
cytometric analyses showed this patient’s NK cells did not
produce IFN-g when they were stimulated with IL-12 plus
IL-15 or IL-12 plus IL-18 (Fig 1). On the other hand,
approximately 20% of the NK cells from the age-matched healthy
control subject produced IFN-g when they were stimulated with
IL-12 plus IL-15, and 85% of the NK cells produced IFN-g
when they were stimulated with IL-12 plus IL-18 (Fig 1). When
NK cells were stimulated with a combination of the 3 cytokines,
almost all NK cells from the healthy control subject produced
IFN-g, whereas only 12% of the NK cells from the patient
FIG 1. Decreased IFN-g production by IL-12Rb1–deficient NK cells in response to IL-12 in combination
with IL-15, IL-18, or both. PBMCs were stimulated with different combinations of IL-12 (10 ng/mL), IL-15
(10 ng/mL), and IL-18 (50 ng/mL) for 16 hours or with phorbol 12-myristate 13-acetate (50 ng/mL) and
ionomycin (1 mmol/L) for 6 hours. For the last 6 to 8 hours, monensin was added to the culture. Then
cell-surface receptor expression and intracellular IFN-g production were determined by using flow
cytometry. Lymphocytes were electronically gated based on forward- and side-scatter parameters, and
NK cells were identified by the CD32CD561 phenotype.
FIG 2. Absence of enhanced effector functions after restimulation by IL-12Rb12deficient NK cells
preactivated with IL-12 plus IL-15 plus IL-18. A, PBMCs were cultured for 16 hours with either low
concentrations of IL-15 (1 ng/mL; ie, nonpreactivated) or with IL-12 (10 ng/mL), IL-15 (10 ng/mL), and
IL-18 (50 ng/mL; ie, preactivated). Next, cells were washed with PBS and cultured in Iscove modified
medium supplemented with 10% human AB serum plus 1 ng/mL IL-15. After 7 days, cells were harvested
and incubated with 721.221 cells for 6 hours in the presence of anti-CD107a and anti-CD107b mAbs. The
secretion inhibitor monensin was added for the last 5 hours. Then CD107a/b expression (left panel) and
TNF-a production (right panel) by NK cells were determined by using flow cytometry. Lymphocytes were
electronically gated based on forward- and side-scatter parameters, and NK cells were identified by
CD32CD561 phenotype. B, PBMCs from the healthy control subject and the second patient were cultured
as in Fig 2, A. After 7 days, cells were harvested and incubated with 721.221 cells or with IL-15 plus IL-18
for 16 hours. Monensin was added for the last 5 hours. Then the IFN-g production by NK cells in response
to restimulation with 721.221 cells (left panel) and IL-15 plus IL-18 (right panel)was measured by using flow
cytometry.
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1192 LETTERS TO THE EDITORexpressed IFN-g. Furthermore, on a per-cell basis, the NK cells
from the patient produced less IFN-g than the NK cells
from the control subject, as shown by a median fluorescence
intensity of 921 for the IFN-g producing NK cells from the
patient versus a median fluorescence intensity of 35,205 for
the IFN-g–producing NK cells from the healthy control subject.
We excluded that the patient had a defect in the IFNG gene or
its regulation because her NK cells and those from the
control subject produced similar amounts of IFN-g in response
to phorbol 12-myristate 13-acetate plus ionomycin (Fig 1).
As expected, these results corroborated that NK cells from an
IL-12Rb1–deficient patient do not respond to IL-12.
Next, we evaluated the role of IL-12–mediated signals in the
generation of NK cells with enhanced effector functions after
restimulation or ‘‘memory-like’’ NK cells, as reported,1,8 after
preactivation with cytokines (Fig 2). We stimulated PBMCs
with IL-12 plus IL-15 plus IL-18 for 16 hours, followed by
washes and a 7-day rest period in vitro, with survival supported
by low concentrations of IL-15. After the resting period, cells
were harvested and coincubated with 721.221 target cells
(EBV-transformed B cells). The expression of CD107 (CD107a
and CD107b) as a surrogate for degranulation triggered by
721.221 tumor cells was measured by using flow cytometry.
Preactivated NK cells from the healthy control subject degranu-
lated more than nonpreactivated NK cells after coincubation
with 721.221 cells (15.4% vs 9.4%; Fig 2,A, left panel). However,
preactivated and nonpreactivated NK cells from the patient
showed similar degranulation after coincubation with 721.221
cells (4.3% vs 4%; Fig 2,A, left panel). These results suggest there
is no significant increase in the degranulation capabilities after
preactivation with cytokines in NK cells lacking IL-12–mediated
signaling.
We also measured TNF-a production by NK cells after
coincubation with 721.221 cells (Fig 2, A, right panel). Similar
to the degranulation results, preactivated NK cells from the
healthy control subject produced more TNF-a than nonpreacti-
vated NK cells (0.51% vs 0.1%; Fig 2, A, right panel), whereas
there were no differences in TNF-a production when preacti-
vated and nonpreactivated NK cells from the patient were
compared (0.02% vs 0.04%; Fig 2, A, right panel). A patient
with a different homozygous null IL12RB1 mutation
(c.1495C>T; p. Q499X) and impaired signal transducer and
activator of transcription 4 phosphorylation on IL-12 stimulation
(see Fig E1 in this article’s Online Repository at www.
jacionline.org) was also tested to confirm that the observed re-
sults were related to the impaired IL-12 signaling rather than
with a particular mutation. Similar to the results obtained with
cells from the first patient, preactivated NK cells from the
healthy control subject produced more IFN-g than nonpreacti-
vated NK cells after restimulation with 721.221 cells (20.4%
vs 14.7%) and IL-15 plus IL-18 (54.1% vs 29.7%; Fig 2, B).
However, preactivated and nonpreactivated NK cells from the
second patient showed similar IFN-g production after restimula-
tion with 721.221 cells (1.29% vs 3.06%) and IL-15 plus IL-18
(3.60% vs 1.94%; Fig 2, B). These results indicate that IL-
12Rb1–deficient NK cells do not have the ability to acquire
enhanced effector functions after restimulation. In addition to
the defect in restimulation, the IL-12Rb1–deficient NK cells
also have a defect in primary activation. The deficiency in
IFN-g production after target and IL-15 plus IL-18 stimulation
and in the absence of preactivation suggests that human NKcells require in vivo priming with IL-12 to acquire full func-
tional reactivity and is consistent with a study by Guia et al.10
Our observations are partly in contradiction to those published
by Romee et al,8 who showed that after preactivation of human
NK cells with IL-12 plus IL-15, restimulation with K562 target
cells led to an increase in IFN-g production without an increase
in the cell-surface expression of CD107a on NK cells. Although
we do not fully understand the reasons for this discrepancy, the
use of different target cells and staining with both anti-CD107a
and anti-CD107b mAbs in our experiments might explain the
differences. In fact, our results are in accordance with those
obtained with the mouse cytomegalovirus infection model, which
demonstrated that degranulation by mouse memory NK cells was
enhanced after stimulation with anti-NK1.1 mAb3 and that
the generation of memory NK cells was dependent on IL-12–
mediated signals.6
Here, using human IL-12Rb1–deficient NK cells, we have
demonstrated the essential role of IL-12–mediated signals in the
generation of human NK cells with enhanced effector function
after restimulation. These findings provide the rationale for
including brief stimulations or preactivation with IL-12 in
combination with other cytokines, such as IL-15 and IL-18, to
generate NK cells with enhanced effector functions (ie, ‘‘mem-
ory-like’’) that might be of great relevance in the field of NK
cell–based immunotherapy and might also unveil a new aspect of
pathophysiology to be considered in IL-12Rb1–deficient
patients.
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Seasonal increases inperipheral innate lymphoid
type 2 cells are inhibited by subcutaneous grass
pollen immunotherapy
To the Editor:
We report for the first time the effects of grass pollen
subcutaneous immunotherapy (SCIT) on the novel subset of
innate lymphoid type 2 cells (ILC2s) in patients with seasonal
allergic rhinitis (SAR). Allergic rhinitis is an IgE-mediated
chronic inflammation of the nasal mucosa, thought largely to be
due to an inappropriate TH2 immune response leading to the pro-
duction of IL-4, IL-5, and IL-13.1 The exclusivity of this concept
has recently been questioned following the emergence of a novel
innate immune cell family, ILC2s.2 ILC2s are morphologically
similar to lymphocytes, but lack T-cell, B-cell, natural-killer
cell, or other cell lineagemarkers and require GATA3 and retinoic
acid receptor–related orphan receptor for their development and
function.3 Originally defined in murine models, ILC2s express
IL-17RB (IL-25R) and ST2 (IL-33R) receptors and produce
substantial amounts of type 2 cytokines, particularly IL-5 and
IL-13, in response to IL-33, IL-25, and thymic stromal lympho-
poietin2,3 and could be important in amplifying allergic inflam-
mation as supported by recent observations in atopic dermatitis.4
SCIT for SAR is highly effective and induces long-term
tolerance.5 Several studies have highlighted that SCIT is
associated with early induction of regulatory T cells and
IgG-associated blocking antibodies followed by suppression of
allergen-specific CD272 CD4 T cells in peripheral blood.5
Although immunotherapy has been shown to suppress allergic
inflammation and type 2 cytokines from T cells, its effects on
ILC2s are yet to be determined.
We recruited 12 participants with moderate to severe SAR
(with positive skin prick test result and raised specific IgE level
[>_0.7 KU/L] to Phleum pratense), 9 participants with a history of
moderate to severe SAR who had received 8 to 36 months
treatment with grass pollen SCIT (P pratense, Alutard; ALK,
Hørsholm, Denmark), and 11 nonatopic (NA) controls (see Table
E1 in this article’s Online Repository at www.jacionline.org). Pe-
ripheral blood samples were collected from all participants both in
(July-August 2013) and outside (December 2013) the grass pollen
season. Clinical symptoms were evaluated using self-reported
visual analog scales. The study was approved by the NRES
Committee North East – Newcastle & North Tyneside 2 and theResearch Office of Royal Brompton and Harefield Hospitals NHS
FoundationTrust.All volunteers providedwritten informedconsent.
We defined ILC2s on the basis of previously published method-
ology.6 Briefly, ILC2s were immunophenotyped using multiparam-
eter flow cytometry. One-hundred microliters of peripheral blood
was immunostained with fluorochrome-labeled mAbs for surface
markers: allophycocyanine-lineage cocktail (CD3, CD14, CD16,
CD19, CD20, CD56; clones: UCTH-1, HCD14, 3G8, HIB19,
2H7, HCD56; BioLegend, London, United Kingdom), peridinium
chlorophyll protein-Cy5.5 antihuman CD127 (clone: eBioRDR5;
eBioscience, Hatfield, United Kingdom), phycoerythrin-anti ST2
(clone: 97203; R&D), V450 antihuman CRTH2 (clone: BW16;
BD Biosciences, Oxford, United Kingdom), and phycoerythrin-
Cy7 antihuman CD117 (clone: 104D2; eBioscience). Erythrocytes
were subsequently lysed, fixed, and permeabilized to allow intracel-
lular staining with fluorescein isothiocyanate antihuman IL-13
(clone: PVW13-1; eBioscience). Lineage-negative lymphocytes
that expressed prostagladin D2 receptor (CRTH2) and IL-7
receptor (CD127) were considered ILC2s6 (Fig 1, A).
The proportion of Lin2CD1271CRTH21 cells (ILC2s) in
peripheral blood was comparable to that reported in a previous
study (1%-20% of lineage negative lymphocytes)6 and they
expressed the IL-33 receptor (ST2) (Fig 1, A and F). ILC2s
were 58% higher in the SAR group during the pollen season
than during out of season (P 5 .007). In contrast, there was no
change in ILC2s over the same time period for SCIT and
NA groups (Fig 1, C; see Tables E3 and E4 in this article’s
Online Repository at www.jacionline.org). During the pollen
season, the proportions of ILC2s were elevated in the SAR
group (median [interquartile range], 14.8 [2.99]) compared
with the SCIT group (9.34 [3.45]; P 5 .03) and NA (7.34
[4.86]; P < .001). Because CD117 (c-kit) has been reported as a
surface marker for identifying a subtype of ILC2s,3 we
enumerated the proportion of CD1171 ILC2s in our population.
Similarly, CD1171 ILC2sweremore prominent in the SAR group
than in SCIT and NA groups (Fig 1, B and D and Tables E3 and
E4). We report that peripheral blood ILC2s during the pollen
season are elevated in patients with SAR than in NA patients
(2-fold; P < .001). A possible explanation for these findings is
that we immunostained ILC2s from whole blood rather than
isolated peripheral blood mononuclear cells. Also, our observed
elevation of ILC2s was detectable only during the pollen season.
These findings highlight the effect of natural grass pollen allergen
exposure in increasing ILC2 numbers in peripheral blood as has
recently been observed following experimental nasal challenge
with cat allergen in cat-allergic subjects.7 Although most subjects
with SAR were not monosensitized, their symptoms were largely
confined to the grass pollen season (P < .001) (Fig 1,G; see Table
E2 in this article’s Online Repository at www.jacionline.org),
with no perennial symptoms requiring more than occasional
antihistamine use. SCIT-treated subjects reported markedly less
seasonal symptoms than did untreated subjects with SAR
(Fig 1, G, and Table E2). Moreover, in allergic individuals, there
was a correlation between visual analog scales and the proportion
of ILC2s during the pollen season (r5 0.52, P5 .02) (Fig 1, H).
IL-13 has been recognized as the major cytokine produced by
ILC2s and plays a major role in allergic inflammation. We
therefore identified the proportion of ex-vivo IL-131 ILC2s in
peripheral blood. The seasonal increase in IL-131 ILC2s was
inhibited after SCIT treatment. IL-131 ILC2s were almost
2-fold higher in the SAR group (3.06 [0.78]) than in both SCIT
FIG E1. Genetic and phenotypic characterization of IL-12Rb1 deficiency in the second patient. A, Coding
exons and adjacent splicing sites within the IL12RB1 gene from the second patient were PCR amplified
and sequenced with the Sanger technique. Results showed a mutation at exon 13, adding to a premature
stop codon. The test result was IL12RB1 NM_005535 c.1495C>T, p.Q499X homozygous. B, IL-12Rb1
cell-surface expression on PBMCs from 2 healthy donors and the second patient. Cells were stimulated
with anti-CD3 and anti-CD28 (1 mg/mL) antibodies plus IL-2 (10 ng/mL) for 5 days. After that, cells were
treated with IL-12 (100 ng/mL) for 30 minutes. Lymphocytes were electronically gated based on forward-
and side-scatter parameters. Histograms in gray show the binding of isotype control antibody, and
histograms in black show the binding of anti–IL-12Rb1 antibody. PE, Phycoerythrin. C, PBMCswere cultured
as in Fig E1, B. After that, cells were treated with IL-12 (100 ng/mL) for 30 minutes, and signal transducer
and activator of transcription 4 phosphorylation (p-STAT4) was detected by means of flow cytometric
analysis. Lymphocytes were electronically gated based on forward- and side-scatter parameters. Binding
of anti–p-STAT4 antibody to unstimulated (black) and stimulated (red) cells is shown.
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